KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.

Ahmad Masri, Francesco Cappelli, Margot K Davis, Marianna Fontana, Pablo Garcia-Pavia, Julian D Gillmore, Mazen Hanna, Laura Obici, Scott D Solomon, Brett W Sperry, Nobuhiro Tahara, Márcia Waddington-Cruz, Arnt V Kristen, Rodney H Falk, Sanjiv J Shah, Jose Nativi-Nicolau, Nicholas J Viney, Qingqing Yang, Jersey Chen, Sotirios Tsimikas, Mathew S Maurer

Circ Heart Fail 19(6) e014205

PMID42104840
PMCIDPMC13160239
DOI10.1161/CIRCHEARTFAILURE.126.014205
发表日期2026-05-09
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand-conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I-III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu; Unique identifier: EudraCT number 2019-002835-27.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Study design of the CARDIO-TTRansform trial. *Locally approved and available treatments for ATTR-CM (e.g., tafamidis, tafamidis meglumine, acoramidis). †Patients stratified by New York Heart Association Functional Classification (I and II vs. III), TTR status (variant vs wild-type), 6MWT distance (≤350 m vs >350 m), and treatment at baseline with TTR stabilizer (Yes vs No). ‡Primary endpoint at Week 140. §Up to 36 months or until after eplontersen is approved and available in the site’s country. If eplontersen is not yet available after 36 months, the participant may continue to participate in the study (under an abbreviated monitoring schedule) until they complete an additional 36 months or eplontersen becomes commercially available in the site’s country or the last participant completes 36 months. ¶CV clinical events include hospitalization for myocardial infarction, hospitalization for heart failure (HF), hospitalization for arrhythmia, hospitalization for stroke/transient ischemic attacks, HF urgent visits to emergency department or HF clinics requiring administration of intravenous diuretics for improvement. KCCQ-OS indicates Kansas City Cardiomyopathy Questionnaire-Overall Summary; OLE, open-label extension; SoC, standard of care; and SC, subcutaneous.
非 KM Figure
Figure 2Figure 2. Countries enrolling in CARDIO-TTRansform. Countries colored dark blue are those enrolling in CARDIO-TTRansform. UK indicates United Kingdom; and USA, United States of America.
非 KM Figure